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 Mononuclear phagocyte 
depletion strategies in models 
of acute kidney disease: what 
are they trying to tell us ? 
 Matthew D.  Griffin 1 
 Mononuclear phagocytes (macrophages, dendritic cells, and 
monocytes) play a complex role in kidney disease. Techniques 
for selectively depleting them in rodents have made important 
contributions but have also generated some contradictory results. 
Ferenbach  et al. report that two widely used mononuclear phagocyte 
depletion techniques differentially affect early severity of renal 
ischemia / reperfusion injury and provide evidence that this may 
be due to a residual, protective subset that persists in the kidney 
after one of the two techniques. 
 Kidney International (2012)  82, 835 – 837.  doi: 10.1038/ki.2012.164 
 Th e healthy rodent or human kidney con-
tains a plentiful population of bone mar-
row-derived myeloid cells with phenotypic 
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and functional characteristics that overlap 
with those of classical macrophages and 
dendritic cells. 1,2 Th e fact that these cells, 
located predominantly in the interstitium, 
have been variously referred to as renal 
macrophages and renal dendritic cells in 
the literature may, to some degree, have 
hampered progress in broadly understand-
ing their biological roles. For this reason, 
the (older) term mononuclear phagocyte 
(MoPh) has more recently been used as a 
broader descriptor. 1,2 Multicolor flow 
cytometry studies in mice suggest that 
resident renal MoPhs (rMoPhs) consist of 
at least two major histocompatibility com-
plex class II-expressing sub-populations, a 
predominant (  >  90 % ), CD11b   +   subset and 
a less abundant, CD11b   −   CD103   +   subset, 
although the functional signifi cance of 
each remains poorly defined. 1 During 
health, these cells have a slow turnover rate 
(2 – 8 weeks) with replacements derived 
from the common macrophage and 
dendritic precursor (MDP) in the bone 
marrow via circulating monocytes and / or 
a pre-dendritic-cell precursor. 1,2 In the 
setting of acute or chronic renal injury, 
the resident rMoPhs are supplemented by 
an infl ux of monocytes from the circula-
tion, which themselves undergo activation 
and are capable of differentiating into 
functionally heterogeneous infl ammatory 
macrophages and dendritic cells. 1 
 Given that the full functional spectrum 
of the mononuclear phagocytic system 
(which encompasses monocytes, macro-
phages, dendritic cells, and cells of inter-
mediate phenotype) includes intense 
proinfl ammatory responses, microbial and 
cell killing, antigen uptake and presenta-
tion to the T-cell compartment, counter-
regulation of innate and adaptive immune 
responses, promotion of tissue healing, and 
regeneration and induction of fi brosis, it 
is not surprising that there is very high 
interest in better understanding and mani-
pulating this system in the context of renal 
diseases. 1 
 For the kidney, as for other organs, the 
most commonly addressed issue regarding 
the mononuclear phagocytic system and 
its individual cellular components has 
been their role in the severity of and recov-
ery from acute injury of diverse causes. In 
addition to its unequivocal clinical rele-
vance, the experimental setting of acute 
kidney injury (AKI) allows for the 
responses of both resident and infi ltrating 
rMoPhs to be determined from a  ‘ standing 
start ’ and to be tracked over time during 
the course of a relatively predictable series 
of events. However, as the complexity of 
the mononuclear phagocytic system has 
revealed itself over the past decade, it has 
become clear that the veracity of conclu-
sions drawn from studies of rMoPhs 
during AKI is only as good as the tools 
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available to accurately defi ne and assay the 
cells of interest. For example, the approach 
of enumerating macrophages on the basis 
of immunohistochemical staining for a 
single cell-surface marker such as CD68 or 
F4 / 80 has limited value for discriminating 
individual rMoPh subtypes and reveals 
little of the functional roles being played. 
 One experimental approach that holds 
particular promise for distinguishing 
harmful and benefi cial eff ects of rMoPhs 
during AKI is that of timed depletion in 
the context of a relevant injury model. A 
number of systems have been developed 
for the purpose of selective  in vivo deple-
tion of MoPhs in rodent species. Th ose that 
have been applied to models of acute renal 
disease are the administration of liposomal 
clodronate (which results in widespread 
death of phagocytic cells within 24 – 48  h) 
and transgenic expression of the diphtheria 
toxin receptor (DTR) in cells expressing 
the myeloid cell-specifi c integrin chains 
CD11b and CD11c (in which administra-
tion of diphtheria toxin (DT) results in 
rapid death of CD11b   +   or CD11c   +   cells, 
respectively). In each of these models, 
MoPh depletion is systemic (including the 
kidney), dose-dependent, limited in dura-
tion (typically 2 – 4 days), and potentially 
associated with  ‘ off -target ’ eff ects. 3 
While the incorporation of these deple-
tion systems into individual studies has, 
undoubtedly, allowed for key observations 
to be made in the context of the models 
being examined, the results have also gene-
rated some interesting controversies as to 
whether rMoPh responses following AKI 
and other acute kidney diseases are pre-
dominantly proinfl ammatory (harmful), 
anti-infl ammatory (benefi cial), or inher-
ently variable. 1 For instance, pre-depletion 
of MoPhs with clodronate was shown to 
ameliorate injury and infl ammation in renal 
ischemia / reperfusion injury (IRI) in rats 
and was used to identify resident 
CD11c   +   CD11b   +   F4 / 80   +   rMoPhs as the 
predominant early source of tumor necrosis 
factor and other proinfl ammatory media-
tors in mouse IRI. 4,5 In contrast, MoPh 
depletion prior to or coincident with cispla-
tin-induced AKI in CD11c-DTR mice 
was associated with exacerbation of early 
parenchymal injury. 6 In acute glomerulo-
nephritis, early depletion of CD11c   +   MoPhs 
resulted in aggravation of disease, 7 but later 
depletion in CD11c-DTR and CD11b-DTR 
mice was associated with amelioration of 
injury. 8,9 While these observations may well 
refl ect phenotypic and functional variances 
of rMoPhs in diff erent disease models and 
at diff erent time points following onset of 
injury, it is interesting to consider that there 
are important caveats associated with each 
of the available depletion systems and to 
note that the studies to date have not directly 
compared experimental results obtained 
with two or more of these techniques. 
 Ferenbach  et al. 10 (this issue) now address 
this by comparing the effects of rMoPh 
depletion by liposomal clodronate admin-
istration with those of DT administration 
to CD11b-DTR mice prior to the initiation 
of moderate IRI. 10 In their initial experi-
ment, the authors observed that, while a 
single dose of liposomal clodronate deliv-
ered 24  h before renal artery clamping pro-
vided a protective effect against acute 
tubular necrosis and renal functional 
impairment at 24  h after injury, rMoPh 
depletion by DT administration had no 
protective eff ect. In a revealing follow-up 
experiment, they then demonstrated 
that the protective eff ect of clodronate was 
abolished when clodronate and DT were 
coadministered to the CD11b-DTR mice 
before IRI. Th is result raised the possibility 
that a single dose of liposomal clodronate 
in this setting was associated with selective 
retention of a protective population of 
CD11b   +   cells that was eff ectively removed 
by DT. Consistent with this interpretation, 
DT administration was shown to cause 
more profound depletion of circulating and 
intrarenal F4 / 80   +   cells, while clodronate 
more eff ectively removed F4 / 80   +   cells from 
the spleen and liver. A more detailed analy-
sis of the intrarenal MoPhs that persisted 
aft er liposomal clodronate indicated that 
these were enriched for expression of 
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Possible interpretations:
 Figure 1  |  Multiple potential interpretations of the influence of MoPh depletion techniques 
on the severity of acute kidney injury in rodent models. Administration of MoPh-depleting 
agents or relevant vehicle controls to experimental animals 1 to 2 days before induction of AKI (or 
at other time points) is a commonly used strategy for determining whether resident and / or early 
infiltrating rMoPhs exert harmful or protective effects on subsequent renal functional decline and 
renal structural injury. As is shown here and highlighted by the results of Ferenbach  et al. , 10 the 
basic observations of improvement or worsening of AKI in such experiments are compatible with 
multiple interpretations and may require additional experimental approaches before accurate 
conclusions can be made. AKI, acute kidney injury; MoPh, mononuclear phagocyte; rMoPh, renal 
mononuclear phagocyte. 
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CD11c — a marker that is oft en considered 
to be specific for dendritic cells in the 
mouse but is coexpressed with the  ‘ macro-
phage markers ’ CD11b and F4 / 80 on the 
predominant resident rMoPh population. 1 
Interestingly, the proportion of these renal 
CD11c   +   cells that coexpressed the man-
nose receptor (CD206), a surface marker 
that has been linked to alternatively acti-
vated (M2) macrophages, 11 was increased 
following clodronate administration. 
Importantly, Ferenbach  et al. 10 also ana-
lyzed cytokine and chemokine levels in pre- 
and post-IRI sera to address the possibility 
that the protective eff ect of clodronate was 
mediated by a systemic surge of anti-
infl ammatory mediators induced by wide-
spread apoptosis of phagocytes. In this 
analysis, clodronate-treated animals had a 
predictable early rise in CCL2 (MCP-1) 
compared with control-treated animals 
but did not demonstrate raised systemic 
levels of either proinfl ammatory (tumor 
necrosis factor, interleukin-12, interferon-
  ) or anti-infl ammatory (interleukin-10, 
interleukin-6) cytokines. 
 Characterization of the CD11c   +   rMoPhs 
that remained aft er liposomal clodronate 
in the study of Ferenbach  et al. 10 was 
limited to surface-marker expression and 
did not directly identify a localized anti-
infl ammatory or cytoprotective mechanism 
of action. Th is particular issue now merits 
further study in clodronate-treated mice, as 
does the question of whether a subset of 
resident CD206   +   MoPhs exists in the 
unmanipulated kidney that is inherently 
anti-infl ammatory in its response to acute 
injury. Overall, however, the results con-
vincingly demonstrate signifi cant diff er-
ences between the two depletion strategies 
and highlight the fact that inaccurate con-
clusions might have been made regarding 
the role of MoPhs in early IRI had either 
approach been used in isolation. In addition 
to presenting further evidence for func-
tional heterogeneity of rMoPhs during AKI, 
the study of Ferenbach  et al. 10 also provides 
important insights for the application and 
interpretation of depletion techniques in 
the context of acute tissue injury models. As 
illustrated in  Figure 1 , the range of possible 
explanations for basic experimental out-
comes in the absence or presence of MoPh 
depletion is broader than might initially be 
assumed. Even the lack of a major infl uence 
on severity of injury (as was observed in this 
study for DT-mediated depletion in CD11b-
DTR mice) may result from a complex 
infl uence on multiple functional responses. 
Th e complexity of interpreting such exper-
iments is further highlighted in a recent 
report by Tittel  et al. in which an unex-
pected neutrophilia was found to occur and 
to be associated with deceptive results at 
varying time points following DT adminis-
tration in multiple strains of CD11c-DTR 
mice. 3 Th us, it is essential for investigators 
using these techniques to remain fl exible in 
their thinking regarding the explanation for 
disease-modifying eff ects of rMoPh deple-
tion and to experimentally address as many 
potential interpretations as possible. Th e 
report by Ferenbach  et al. , 10 as well as the 
work of others, 1 indicates several strategies 
that can be applied: 
 (1)  comparison of results of two or 
more depletion techniques; 
 (2)  careful enumeration and pheno-
typic characterization of MoPhs 
remaining in the tissue of interest 
for each depletion technique used; 
 (3)  analysis of system-wide infl amma-
tory and immunological activities 
occurring during the time frame of 
the disease model being studied; 
 (4)  isolation and functional analysis of 
putative pro- and anti-infl ammatory 
MoPh subtypes from injured tissue 
of non-depleted animals; 
 (5)  performance of  ‘ add-back ’ experi-
ments in which the eff ect of replen-
ishing functionally distinct MoPhs 
in depleted animals is quantifi ed. 
 Finally, it should be emphasized that care-
ful application of the available depletion 
techniques, complemented by additional 
experimental approaches, has provided 
other novel insights into rMoPh activ-
ity during health and disease. Th ese have 
included insights into the relative kinet-
ics of individual rMoPh sub-populations 
following AKI 11,12 and demonstration of 
the role played by rMoPhs in localized 
activation of eff ector T cells within the 
kidney. 13,14 For the future, it is likely that 
the development of more precise appro-
aches to defi ning and eliminating indi-
vidual MoPh sub-populations along with 
continued pro gress in understanding the 
diversity of rMoPh functional responses 
during experimental acute or chronic 
injury will open the fi eld to the design of 
novel targeted anti-infl ammatory and an-
tifi brotic interventions in human kidney 
diseases. 
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